Opinion

Video

Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

Author(s):

Catherine C. Coombs, MD,Matthew S. Davids, MD, MMSc

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

Video content above is prompted by the following:

  • Briefly share perspective/insights on emerging novel agents in R/R CLL: 2nd gen BCL2 inhibitors 
Related Videos
Guru P. Sonpavde, MD
Shaji Kumar, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Related Content
November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Nicole Lamanna, MD, associate clinical professor, medicine, Hematologic Malignancies Section, Hematology/Oncology Division, Columbia University Herberg Irving Comprehensive Cancer Center
November 25th 2024

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

NX-5948 for R/R CLL/SLL | Image Credit: © Dr_Microbe - stock.adobe.com
November 21st 2024

EMA Grants PRIME Designation to NX-5948 for R/R CLL/SLL

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA
November 20th 2024

FDA Approves New Drug Labeling for Fludarabine Phosphate in CLL

Maurie Markman, MD, president, Medicine & Science, City of Hope Atlanta, Chicago, and Phoenix
November 20th 2024

Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients